Table 3 Univariate analysis of the correlation between clinical features and PFS
Variable | N | Median PFS (months) | P |
|---|---|---|---|
ECOG PS | |||
 0–1 | 220 | 11.7 | 0.159 |
 2 | 25 | 10.2 |  |
EGFR mutations | |||
 Yes | 52 | 10.8 | 0.212 |
 No | 69 | 15.0 |  |
PD-L1 expression levels | |||
 <1% | 77 | 6.4 | 0.000 |
 1–49% | 62 | 13.4 |  |
  ≥ 50% | 55 | not reached |  |
 Unknown | 59 | 9.1 |  |
Histology | |||
 Adenocarcinoma | 133 | 10.8 | 0.086 |
 Squamous cell carcinoma | 112 | 14.3 |  |
Corticosteroid interference | |||
 Yes | 8 | 9.0 | 0.015 |
 No | 237 | 11.4 |  |
Abx treatment | Â | Â | Â |
 Yes(≥7 days) | 35 | 5.0 | 0.002 |
 Yes(<7 days) | 37 | 12.7 |  |
 No | 173 | 13.4 |  |
Lines of therapy | |||
 1 | 132 | 11.4 | 0.707 |
 2 | 113 | 10.0 |  |